Detalhe da pesquisa
1.
Acalabrutinib, venetoclax and obinutuzumab in relapsed CLL: Final efficacy and ctDNA analysis of the CLL2-BAAG trial.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620072
2.
Reassessing the Chronic Lymphocytic Leukemia International Prognostic Index in the era of targeted therapies.
Blood;
2024 Apr 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38620092
3.
COVID-19 in patients with hematologic malignancy.
Blood;
140(3): 236-252, 2022 07 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35544585
4.
The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia.
Blood;
139(2): 177-187, 2022 01 13.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34758069
5.
Hybrid immunity to SARS-CoV-2 in patients with chronic lymphocytic leukemia.
Eur J Haematol;
112(5): 788-793, 2024 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38311570
6.
Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations.
Blood;
138(19): 1805-1816, 2021 11 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34086865
7.
International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia.
Blood;
135(21): 1859-1869, 2020 05 21.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32267500
8.
Bendamustine, followed by ofatumumab and ibrutinib in chronic lymphocytic leukemia (CLL2-BIO): primary endpoint analysis of a multicenter, open-label phase-II trial.
Haematologica;
106(2): 543-554, 2021 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32107341
9.
Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic.
Acta Haematol;
144(5): 508-518, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33631756
10.
COVID-19 complicated by parainfluenza co-infection in a patient with chronic lymphocytic leukemia.
Eur J Haematol;
105(4): 508-511, 2020 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32575156
11.
Rapid response infrastructure for pandemic preparedness in a tertiary care hospital: lessons learned from the COVID-19 outbreak in Cologne, Germany, February to March 2020.
Euro Surveill;
25(21)2020 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32489176
12.
Cardiotoxicity in patients treated with acalabrutinib.
Blood;
140(20): 2096-2097, 2022 11 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36394904
13.
Mode of progression after first line treatment correlates with outcome of chronic lymphocytic leukemia (CLL).
Am J Hematol;
94(9): 1002-1006, 2019 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31222797
14.
Infections in patients with chronic lymphocytic leukemia treated with time limited targeted drug combinations.
Am J Hematol;
2024 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38757754
15.
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trial.
Am J Hematol;
99(6): 1192-1195, 2024 Jun.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38578022
16.
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.
Lancet Oncol;
19(9): 1215-1228, 2018 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30115596
17.
Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Br J Haematol;
183(5): 727-735, 2018 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-30460980
18.
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.
Blood;
127(2): 208-15, 2016 Jan 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-26486789
19.
CLL2-BXX Phase II trials: sequential, targeted treatment for eradication of minimal residual disease in chronic lymphocytic leukemia.
Future Oncol;
14(6): 499-513, 2018 Mar.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29465308
20.
SARS-CoV-2-specific cellular response following third COVID-19 vaccination in patients with chronic lymphocytic leukemia.
Haematologica;
107(10): 2480-2484, 2022 10 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35734927